Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Company Performance - Shares of Adaptive Biotechnologies (ADPT) have increased by 14.5% over the past month, reaching a new 52-week high of $12.93 [1] - The stock has gained 111.2% since the beginning of the year, outperforming the Zacks Medical sector, which declined by 6.6%, and the Zacks Medical - Biomedical and Genetics industry, which saw a return of 0.6% [1] Earnings and Revenue - Adaptive Biotechnologies has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters [2] - In the latest earnings report on August 5, 2025, the company reported an EPS of -$0.17, surpassing the consensus estimate of -$0.24, and beat the revenue estimate by 18.47% [2] - For the current fiscal year, the company is expected to post earnings of -$0.78 per share on revenues of $227.14 million, reflecting a 27.78% change in EPS and a 26.93% change in revenues [3] - For the next fiscal year, earnings are projected to be -$0.59 per share on revenues of $271.06 million, indicating year-over-year changes of 23.72% and 19.34%, respectively [3] Valuation Metrics - Despite reaching a 52-week high, the valuation metrics are crucial to assess if the stock has become overvalued [4] - The Zacks Style Scores indicate that Adaptive Biotechnologies has a Value Score of F, while its Growth and Momentum Scores are both A, resulting in a VGM Score of B [6] Zacks Rank - The current Zacks Rank for Adaptive Biotechnologies is 2 (Buy), supported by a solid earnings estimate revision trend [7] - The recommendation is for investors to select stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, suggesting that Adaptive Biotechnologies may have further upside potential [8] Industry Comparison - In comparison to industry peers, Puma Biotechnology, Inc. (PBYI) also shows promise with a Zacks Rank of 2 (Buy) and a Value Score of A [9] - Puma Biotechnology reported a 36.36% earnings beat in the last quarter and is expected to post earnings of $0.65 per share on revenues of $216.32 million for the current fiscal year [10] - The Medical - Biomedical and Genetics industry ranks in the bottom 59% of all industries, but there are still positive tailwinds for both ADPT and PBYI [11]